Efficacy and tolerability of a β-1 selective β blocker, bisoprolol, as a first-line antihypertensive in Indian patients diagnosed with essential hypertension (BRIGHT): An open-label, multicentric observational study

BMJ Open

Volumn 2, Issue 3, 2012, Pages

  Channaraya, V ^a   Marya, R K ^b   Somasundaram, M ^c   Mitra, Debashish ^d   Tibrewala, K D ^b  

^a KEMPEGOWDA INSTITUTE OF MEDICAL SCIENCES   (India)

^b Madras Medical College ^*

^c MADRAS MEDICAL COLLEGE   (India)

^d RNT Institute of Cardiac Sciences   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BISOPROLOL;

ADULT; ARTICLE; BLOOD PRESSURE REGULATION; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; ESSENTIAL HYPERTENSION; FATIGUE; FEMALE; HEADACHE; HEART RATE; HUMAN; INDIAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA AND VOMITING; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PHASE 4 CLINICAL TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

EID: 84862311752     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2011-000683     Document Type: Article

References (35)

1. Gaziano TA, Opie LH, Weinstein MC. Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis. Lancet 2006;368:679-86.
2. Rodgers A, Lawes C, MacMahon S. Reducing the global burden of blood pressure-related cardiovascular disease. J Hypertens Suppl 2000;18:S3-6. (Pubitemid 30487405)
3. Vasan RS, Larson MG, Leip EP, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001;345:1291-7.
4. Yusuf S, Reddy S, Ounpuu S, et al. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation 2001;104:2746-53. (Pubitemid 33108145)
5. Vikrant S, Tiwari SC. Hypertension - Pathogenesis and Pathophysiology. Indian Acad Clin Med 2001;2:141-61.
6. Gupta R. Meta-analysis of prevalence of hypertension in India. Indian Heart J 1997;49:450.
7. Gupta R. Trends in hypertension epidemiology in India. J Hum Hypertens 2004;18:73-8. (Pubitemid 38247814)
8. Mohan V, Deepa M, Farooq S, et al. Prevalence, awareness and control of hypertension in Chennai - The Chennai Urban Rural epidemiology study (CURES-52). J Assoc Physicians India 2007;55:326-32.
9. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: global Burden of Disease Study. Lancet 1997;349:1498-504. (Pubitemid 27216360)
10. Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med 1993;328:914-21. (Pubitemid 23086643)
11. Neutel JM, Smith DH, Ram CV, et al. Application of ambulatory blood pressure monitoring in differentiating between antihypertensive agents. Am J Med 1993;94:181-7. (Pubitemid 23046444)
12. Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA 1997;277:739-45. (Pubitemid 27106227)
13. Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of hypertension Task Force document. J Hypertens 2009;27:2121-58.
14. Buhler FR, Berglund G, Anderson OK, et al. Double blind comparison of cardioselective beta blockers in bisoprolol and atenolol in hypertension: the Bisoprolol International Multicenter study (BIMS). J Cardiovasc Pharmacol 1986;8(Suppl 11):S122-7. (Pubitemid 17086498)
15. Lenfant C, Chobanian AV, Jones DW, et al. Seventh report of the Joint National committee on the prevention, detection, evaluation, and treatment of high blood pressure (JNC 7): resetting the hypertension sails. Hypertension 2003;41:1178-9. (Pubitemid 36706061)
16. Tomlinson B, Dalal JJ, Huang J, et al. The role of beta blockers in the management of hypertension: an Asian perspective. Curr Med Res Opin 2011;27:1021-33.
17. Jackson R, Barham P, Bills J, et al. Management of raised blood pressure in New Zealand: a discussion document. BMJ 1993;307:107-10. (Pubitemid 23189574)
18. Ogilvie RI, Burgess ED, Cusson JR, et al. Report of the Canadian hypertension Society consensus Conference: 3. Pharmacologic treatment of essential hypertension. CMAJ 1993;149:575-84. (Pubitemid 23340855)
19. Arif AF, Kadam GG, Joshi C. Treatment of hypertension: postmarketing surveillance study results of telmisartan monotherapy, fixed dose combination of telmisartan + hydrochlorothiazide/amlodipine. J Indian Med Assoc 2009;107:730-3.
20. Johns TE, Lopez LM. Bisoprolol: is this just another beta-blocker for hypertension or angina? Ann Pharmacother 1995;29:403-14.
21. Haeusler G, Schliep HJ, Schelling P, et al. High beta 1-selectivity and favourable pharmacokinetics as the outstanding properties of bisoprolol. J Cardiovasc Pharmacol 1986;8(Suppl 11):S2-15.
22. Harting J, Becker KH, Bergmann R, et al. Pharmacodynamic profile of the selective beta 1-adrenoceptor antagonist bisoprolol. Arzneimittelforschung 1986;36:200-8. (Pubitemid 16164496)
23. Kaumann AJ, Lemoine H. Direct labelling of myocardial beta 1-adrenoceptors. Comparison of binding affinity of 3H-(-)-bisoprolol with its blocking potency. Naunyn Schmiedebergs Arch Pharmacol 1985;331:27-39. (Pubitemid 16191714)
24. Klockow M, Greiner HE, Haase A, et al . Studies on the receptor profile of bisoprolol. Arzneimittelforschung 1986;36:197-200. (Pubitemid 16164495)
25. Manalan AS, Besch HR, Watanabe AM. Characterization of [3H](+/-) carazolol binding to beta-adrenergic receptors. Application to study of beta-adrenergic receptor subtypes in canine ventricular myocardium and lung. Circ Res 1981;49:326-36. (Pubitemid 11053293)
26. Schliep HJ, Harting J. Beta 1-selectivity of bisoprolol, a new beta-adrenoceptor antagonist, in anesthetized dogs and guinea pigs. J Cardiovasc Pharmacol 1984;6:1156-60. (Pubitemid 15193273)
27. Schliep HJ, Schulze E, Harting J, et al. Antagonistic effects of bisoprolol on several beta-adrenoceptor-mediated actions in anaesthetized cats. Eur J Pharmacol 1986;123:253-61. (Pubitemid 16055458)
28. Wellstein A, Palm D, Belz GG. Affinity and selectivity of beta-adrenoceptor antagonists in vitro. J Cardiovasc Pharmacol 1986;8(Suppl 11):S36-40. (Pubitemid 17086482)
29. Janka HU, Ziegler AG, Disselhoff G, et al. Influence of bisoprolol on blood glucose, glucosuria, and haemoglobin A1 in noninsulin-dependent diabetics. J Cardiovasc Pharmacol 1986;8(Suppl 11):S96-99. (Pubitemid 17086494)
30. Fogari R, Zoppi A, Tettamanti F, et al. Beta-blocker effects on plasma lipids in antihypertensive therapy: importance of the duration of treatment and the lipid status before treatment. J Cardiovasc Pharmacol 1990;16(Suppl 5):S76-80.
31. Frithz G, Weiner L. Long-term effects of bisoprolol on blood pressure, serum lipids, and HDL-cholesterol in patients with essential hypertension. J Cardiovasc Pharmacol 1986;8(Suppl 11):S134-8. (Pubitemid 17086500)
32. Law MR, Wald NJ, Morris JK, et al. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003;326:1427.
33. Badar VA, Hiware SK, Shrivastava MP, et al. Comparison of nebivolol and atenolol on blood pressure, blood sugar, and lipid profile in patients of essential hypertension. Indian J Pharmacol 2011;43:437-40.
34. Fogari R, Zoppi A, Corradi L, et al . Beta-blocker effects on plasma lipids during prolonged treatment of hypertensive patients with hypercholesterolemia. J Cardiovasc Pharmacol 1999;33:534-9. (Pubitemid 29164815)
35. Frithz G, Weiner L. Effects of bisoprolol, dosed once daily, on blood pressure and serum lipids and HDL- cholesterol in patients with mild to moderate hypertension. Eur J Clin Pharmacol 1987;32:77.